Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966028 · ClinicalTrials.gov registry record · Phase 2
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
A Phase 2 study, sponsored by Sanifit Therapeutics S. A..
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT02966028 is a Phase 2 study that has completed, run by Sanifit Therapeutics S. A.. The registered enrollment target is 274 participants.
The verdict
NCT02966028, a Phase 2 study, has completed, sponsored by Sanifit Therapeutics S. A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
Interventions
- DRUG Placebo
- DRUG SNF472
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966028
The ClinicalTrials.gov registry entry for NCT02966028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanifit Therapeutics S. A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02966028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02966028 about?
NCT02966028 is a clinical study titled "Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)". The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
What is the current status of trial NCT02966028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2016-11. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02966028?
The interventions under investigation include: Placebo (DRUG), SNF472 (DRUG).
Who is sponsoring clinical trial NCT02966028?
This trial is sponsored by Sanifit Therapeutics S. A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.